Health

LiberNovo Launches Black Friday Savings: Redefine Your Workspace for Health

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- The season for serious deals has arrived, and LiberNovo today launched its Black Friday & Cyber Monday (BFCM) sale across across the U.S. and Canada—with limited-time discounts of up to 34% on its flagship product,the LiberNovo Omni

2025-11-11 00:00 1556

TraceLink Customers Demonstrate Readiness as DSCSA Dispenser Deadline Arrives

TraceLink Continues to Set the Standard for United States Drug Supply Chain Security (DSCSA) Leadership, Proven by Real-World Success, Industry Adoption, and Superior Service BOSTON, Nov. 10, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestr...

2025-11-10 23:00 1065

Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B

* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...

2025-11-10 21:30 2005

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolyti...

2025-11-10 21:15 1041

Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical...

2025-11-10 21:00 1274

Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo

BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...

2025-11-10 20:30 942

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells(Treg)-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...

2025-11-10 20:06 1060

Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech

BEIJING, Nov. 10, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology Co., Ltd. ("Shunfeng BioTech") for the Cas...

2025-11-10 20:00 841

LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)

SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences  ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in aglobal Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Ch...

2025-11-10 20:00 809

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...

2025-11-10 19:39 798

MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("M ediTrustHealth") signed a strategic cooperation agreement. The...

2025-11-10 14:18 1132

Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions

NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycer...

2025-11-10 12:00 1297

Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress

CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science Forum Organizing Committee ...

2025-11-10 10:01 1287

ICP DAS-BMP Attends MOU Signing Ceremony to Mark a New Milestone in Medical-Grade TPU Materials

HSINCHU, Nov. 10, 2025 /PRNewswire/ -- ICP DAS-BMP participated in the Strategic Memorandum of Understanding (MOU) signing ceremony organized by Towards Buddha Co., Ltd. onOctober 28, where it showcased its R&D achievements and diverse applications in medical-grade TPU materials. Moving forward, ...

2025-11-10 08:45 1070

Xinhua Silk Road: E. China's Weihai City establishes 18 TCM health tourism demonstration bases

BEIJING, Nov. 8, 2025 /PRNewswire/ -- Weihai, a prefecture-level city in east China's Shandong Province, has seen the establishment of 18 traditional Chinese medicine (TCM) health tourism demonstration bases, including the Weihai Tianmu Hot Spring Resort, as the city has emphasized the deep integ...

2025-11-08 20:48 1759

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...

2025-11-08 18:00 1263

inne Debuts at CIIE with Global Launch of Two New Products

SHANGHAI, Nov. 8, 2025 /PRNewswire/ -- The 8th China International Import Expo (CIIE) commenced onNov. 5 in Shanghai, China. The world's leading children's nutrition brand inne® was invited to participate, showcasing a range of its innovative achievements on this international stage and seizing t...

2025-11-08 11:23 1914

2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal Eltaeb

Head of Al Nao Hospital in Sudan recognized for sustaining critical medical care amid civil war and saving hundreds of lives NEW YORK, Nov. 8, 2025 /PRNewswire/ -- The Aurora Humanitarian Initiative announced Thursday evening thatDr. Jamal Eltaeb

2025-11-08 00:03 701

Get Ready for the Holidays as VARON Launches Black Friday Early Access Savings on Oxygen Concentrators

NEW YORK, Nov. 7, 2025 /PRNewswire/ -- As the holiday season approaches, one essential product that continues to improve lives is the oxygen concentrator. For individuals living with chronic respiratory conditions, having reliable access tosupplemental oxygen

2025-11-07 23:31 1516

Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precis...

2025-11-07 22:05 1644
1 ... 10111213141516 ... 874